

Chapter 38

Urticaria and Angioedema

Allen P. Kaplan

REFERENCES

1. Henderson RL Jr, Fleischer AB Jr, Feldman SR: Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. *J Am Acad Dermatol* **43**:1084, 2000
2. Gaig P et al: Epidemiology of urticaria in Spain. *J Invest Allergol Clin Immunol* **14**:214, 2004
3. Weidner C et al: Acute effects of substance P and calcitonin gene-related peptide in human skin—A microdialysis study. *J Invest Dermatol* **115**:1015, 2000
4. Petersen L, Church M, Skov PS: Histamine is released in the wheal but not the flare following challenge of human skin in vivo: A microdialysis study. *Clin Exp Allergy* **27**:284, 1997
5. Sun Y et al: Cellular basis of itch sensation. *Science* **325**:1531, 2009
6. Gorevic P, Kaplan A: The physical urticarias. *Int J Dermatol* **19**:417, 1980
7. Soter N: Physical urticaria/angioedema. *Semin Dermatol* **6**:302, 1987
8. Zweiman B et al: Sequential patterns of inflammatory events during developing and expressed skin late-phase reactions. *J Allergy Clin Immunol* **105**:776, 2000
9. Leznoff A et al: Association of chronic urticaria and angioedema with thyroid autoim. *Arch Dermatol* **119**:636, 1983
10. Leznoff A, Sussman G: Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: A study of 90 patients. *J Allergy Clin Immunol* **84**:66, 1989
11. Kaplan A, Finn A: Autoimmunity and the etiology of chronic urticaria. *Can J Allergy Clin Immunol* **4**:286, 1999
12. Kikuchi Y, Fann T, Kaplan A: Antithyroid antibodies in chronic urticaria and angioedema. *J Allergy Clin Immunol* **112**:218, 2003
13. Gruber B et al: Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. *J Invest Dermatol* **90**:213, 1988
14. Grattan C et al: Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. *Br J Dermatol* **119**:179, 1998
15. Grattan C et al: A serological mediator in chronic idiopathic urticaria—A clinical, immunological and histological evaluation. *Br J Dermatol* **114**:583, 1986
16. Hide M et al: Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. *N Engl J Med* **328**:1599, 1993
17. Grattan C et al: Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. *Clin Exp Allergy* **21**:695, 1992
18. Greaves M: Chronic urticaria. *J Allergy Clin Immunol* **105**:664, 2000
19. Fiebiger E et al: Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? *J Clin Invest* **96**:2606, 1995
20. Tong L et al: Assessment of autoimmunity in patients with chronic urticaria. *J Allergy Clin Immunol* **99**:461, 1997
21. Zweiman B et al: Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. *J Allergy Clin Immunol* **98**:89, 1996
22. Kikuchi Y, Kaplan A: Mechanisms of autoimmune activation of basophils in chronic urticaria. *J Allergy Clin Immunol* **107**:1056, 2001
23. Ferrer M, Kinet J, Kaplan A: Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. *J Allergy Clin Immunol* **101**:672, 1998
24. Ferrer M, Luquin E, Kaplan A: IL3 effect on basophils histamine release upon stimulation with chronic urticaria sera. *Allergy* **58**:802, 2003
25. Ferrer M et al: Secretion of cytokines, histamine and leukotrienes in chronic urticaria. *Int Arch Allergy Immunol* **129**:254, 2002

26. Wedi B et al: Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression—inhibitory effects of anti-inflammatory drugs. *J Allergy Clin Immunol* **105**:552, 2000
27. Niimi N et al: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. *J Invest Dermatol* **106**:1001, 1996
28. Ferrer M, Nakazawa K, Kaplan A: Complement dependence of histamine release in chronic urticaria. *J Allergy Clin Immunol* **104**:169, 1999
29. Fiebiger E et al: Anti-Fcε1Rα autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. *J Clin Invest* **101**:243, 1998
30. Ling M et al: Importance of Antigen Selection in the Detection of Autoantibodies against Fcε1Rα in Chronic Urticaria Patients, in: Lenexa, KS
31. Soundararajan S et al: Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. *J Allergy Clin Immunol* **115**:815, 2005
32. Horn M et al: Human anti-Fcε1Rα autoantibodies isolated from healthy donors cross-react with tetanus toxoid. *Eur J Immunol* **29**:1139, 1999
33. Horn M et al: Conditional autoimmunity mediated by human natural anti-Fc(ε1)Rα autoantibodies? *FASEB J* **15**:2268, 2001
34. Pachlöpnik J et al: Natural anti-Fcε1Rα autoantibodies may interfere with diagnostic tests for autoimmune urticaria. *J Autoimmun* **22**:43, 2004
35. Kikuchi Y, Kaplan A: A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. *J Allergy Clin Immunol* **109**:114, 2002
36. Elias J, Boss E, Kaplan A: Studies of the cellular infiltrate of chronic idiopathic urticaria: Prominence of T-lymphocytes, monocytes, and mast cells. *J Allergy Clin Immunol* **78**:914, 1986
37. Nettis E et al: Mast-cell phenotype in urticaria. *Allergy* **56**:915, 2001
38. Smith C et al: Mast cell number and phenotype in chronic idiopathic urticaria. *J Allergy Clin Immunol* **96**:360, 1995
39. Natbony S et al: Histologic studies of chronic idiopathic urticaria. *J Allergy Clin Immunol* **71**:177, 1983
40. Haas N, Schadendorf D, Henz B: Differential endothelial adhesion molecule expression in early and late whealing reactions. *Int Arch Allergy Immunol* **115**:210, 1998
41. Sabroe R et al: Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-Fcε1Rα or anti-IgE autoantibodies. *J Allergy Clin Immunol* **103**:484, 1999
42. Peters M et al: Localization of eosinophil granule major basic protein in chronic urticaria. *J Invest Dermatol* **81**:39, 1983
43. Grattan C et al: The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. *Int Arch Allergy Immunol* **93**:198, 1990
44. Haas N, Toppe E, Henz B: Microscopic morphology of different types of urticaria. *Arch Dermatol* **134**:41, 1998
45. Lee K et al: Increased expression of endothelial cell adhesion molecules due to mediator release from human foreskin mast cells stimulated by autoantibodies in chronic urticaria sera. *J Invest Dermatol* **118**:658, 2002
46. Ying S et al: C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). *J Immunol* **163**:3976, 1999
47. Sabroe R et al: Classification of anti-Fcε1Rα and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. *J Allergy Clin Immunol* **40**:492, 2002
48. Kern F, Lichtenstein L: Defective histamine release in chronic urticaria. *J Clin Invest* **57**:1369, 1976
49. Sabroe R et al: Anti-Fc(ε1)Rα autoantibodies and basophil histamine releasability in chronic idiopathic urticaria. *J Allergy Clin Immunol* **102**:651, 1998
50. Grattan C et al: Flow cytometric analysis of basophil numbers in chronic urticaria: Basopenia is related to serum histamine releasing activity. *Clin Exp Allergy* **27**:1417, 1997
51. Vonakis B et al: Basophil Fcε1Rα histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. *J Allergy Clin Immunol* **119**:441, 2007

52. Luquin E, Kaplan A, Ferrer M: Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. *Clin Exp Allergy* 35:456, 2005
53. Asero R et al: Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. *J Allergy Clin Immunol* 119:705, 2007
54. Asero R: Predictive value of autologous plasma skin test for multiple nonsteroidal anti-inflammatory drug intolerance. *Int Arch Allergy Immunol* 144:226, 2007
55. Cugno M et al: Expression of tissue factor by eosinophils in patients with chronic urticaria. *Int Arch Allergy Immunol* 148:170, 2009
56. Puccetti A et al: In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. *Clin Exp Allergy* 35:1599, 2005
57. Margolius H: Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. *Clin Rev Allergy Immunol* 16:337, 1998
58. Jacobson S, Kritz M: Some data on two purified kininogens from human plasma. *Br J Pharmacol* 29:25, 1967
59. Muller-Esterl W et al: Limited proteolysis of human low-molecular-mass kininogen by tissue kallikrein. Isolation and characterization of the heavy and the light chains. *Eur J Biochem* 149:15, 1985
60. Kaplan AP, Joseph K, Silverberg M: Pathways for bradykinin formation and inflammatory disease. *J Allergy Clin Immunol* 109:195, 2002
61. Silverberg M et al: Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. *J Biol Chem* 255:7281, 1980
62. Tankersley DL, Finlayson JS: Kinetics of activation and autoactivation of human factor XII. *Biochemistry* 23:273, 1984
63. Mandle RJ, Kaplan A: Hageman factor substrates. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. *J Biol Chem* 252:6097, 1977
64. Bouma B, Griffin J: Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. *J Biol Chem* 252:6432, 1977
65. Kurachi K, Davie E: Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). *Biochemistry* 16:5831, 1977
66. Mandle R, Colman R, Kaplan A: Identification of prekallikrein and high-molecular-weight kininogen as a complex in human pl. *Proc Natl Acad Sci U S A* 73:4179, 1976
67. Thompson R, Mandle RJ, Kaplan A: Association of factor XI and high molecular weight kininogen in human plasma. *J Clin Invest* 60:1376, 1977
68. Kitamura N et al: Structural organization of the human kininogen gene and a model for its evolution. *J Biol Chem* 260:8610, 1985
69. Takagaki Y, Kitamura N, Nakanishi S: Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininog. *J Biol Chem* 260:8601, 1985
70. Joseph K et al: Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). *Proc Natl Acad Sci U S A* 93:8552, 1996
71. Joseph K et al: Interaction of high molecular weight kininogen binding proteins on endothelial cells. *Thromb Haemost* 91:61, 2004
72. Erdos E, Sloane G: An enzyme in human plasma that inactivates bradykinin and kallidins. *Biochem Pharmacol* 11:585, 1962
73. Binkley K, Davis AR: Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. *J Allergy Clin Immunol* 106:546, 2000
74. Bonkowsky H et al: Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. *J Clin Invest* 56:1139, 1975
75. Sheikh I, Kaplan A: Studies of the digestion of bradykinin, Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. *Biochem Pharmacol* 35:1951, 1986
76. Yang H, Erdos E: Second kininase in human blood plasma. *Nature* 215:1402, 1967
77. Sheikh I, Kaplan A: Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. *Biochem Pharmacol* 38:993, 1989
78. Vavrek R, Stewart J: Competitive antagonists of bradykinin. *Peptides* 6:161, 1985
79. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. *Pharmacol Rev* 32:1, 1980

80. Davis A, Perkins M: The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. *Br J Pharmacol* **113**:63, 1994
81. Marceau F: Kinin B1 receptors: A review. *Immunopharmacology* **30**:1, 1995
82. Garafalo J, Kaplan A: Histamine release and therapy of severe dermatographism. *J Allergy Clin Immunol* **68**:103, 1981
83. Soter N et al: Delayed cold-induced urticaria: A dominantly inherited disorder. *J Allergy Clin Immunol* **54**:294, 1977
84. Kaplan A: Unusual cold-induced disorders: Cold-dependent dermatographism and systemic cold urticaria. *J Allergy Clin Immunol* **73**:453, 1984
85. Dover J et al: Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients. *J Am Acad Dermatol* **18**:1289, 1988
86. Estes S, Yung C: Delayed pressure urticaria: An investigation of some parameters of lesion induction. *J Am Acad Dermatol* **5**:25, 1981
87. Barlow R et al: Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. *Br J Dermatol* **131**:341, 1994
88. Kaplan A, Horakova Z, Katz S: Assessment of tissue fluid histamine levels in patients with urticaria. *J Allergy Clin Immunol* **61**:350, 1978
89. Lawlor F et al: Increased interleukin 6, but reduced interleukin 1, in delayed pressure urticaria. *Br J Dermatol* **128**:500, 1993
90. Weiner M, Metzger W, Simon R: Occupationally acquired vibratory angioedema with secondary carpal tunnel syndrome. *Ann Intern Med* **98**:44, 1983
91. Ting S et al: Nonfamilial, vibration-induced angioedema. *J Allergy Clin Immunol* **71**:546, 1983
92. Siebenhaar F et al: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. *J Allergy Clin Immunol* **123**:672, 2009
93. Costanzi J, Coltman CJ: Kappa chain cold precipitable immunoglobulin G (IgG) associated with cold urticaria. I. Clinical observations. *Clin Exp Immunol* **2**:167, 1967
94. Costanzi J, Coltman CJ, Donaldson V: Activation of complement by a monoclonal cryoglobulin associated with cold urtic. *J Lab Clin Med* **74**:902, 1969
95. Gorevic P: Cryopathies: Cryoblobulins and cryofibrinogenemia. In: *Samter's Immunologic Diseases*, vol. 5, edited by M Frank, K Austen, H Claman. Boston, Little Brown, 1995, p. 951
96. Houser D et al: Cold urticaria. Immunologic studies. *Am J Med* **49**:23, 1970
97. Wanderer A et al: Immunologic characterization of serum factors responsible for cold urticaria. *J Allergy Clin Immunol* **48**:13, 1971
98. Grandel K et al: Association of platelet-activating factor with primary acquired cold urticaria. *N Engl J Med* **313**:405, 1985
99. Kaplan A et al: In vivo studies of mediator release in cold urticaria and cholinergic urticaria. *J Allergy Clin Immunol* **55**:394, 1975
100. Ormerod A et al: Prostaglandin D2 and histamine release in cold urticaria unaccompanied by evidence of platelet activation. *J Allergy Clin Immunol* **82**:586, 1988
101. Soter N, Wasserman S, Austen K: Cold urticaria: Release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. *N Engl J Med* **294**:687, 1976
102. Tillie-Leblond I et al: Tumor necrosis factor- α release during systemic reaction in cold urticaria. *J Allergy Clin Immunol* **93**:501, 1994
103. Wasserman S, Austen K, Soter N: The functional and physicochemical characterization of three eosinophilotactic activities released into the circulation by cold challenge of patients with cold urticaria. *Clin Exp Immunol* **47**:570, 1982
104. Wasserman S et al: Cold urticaria. Recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge. *J Clin Invest* **60**:189, 1977
105. Kaplan A et al: Idiopathic cold urticaria: In vitro demonstration of histamine release upon challenge of skin biopsies. *N Engl J Med* **305**:1074, 1981
106. Eady R, Greaves M: Induction of cutaneous vasculitis by repeated cold challenge in cold *Lancet* **1**:336, 1978
107. Eady R et al: Cold urticaria with vasculitis: Report of a case with light and electron microscopic, immunofluorescence and pharmacological studies. *Clin Exp Dermatol* **6**:355, 1981
108. Soter N et al: Cutaneous necrotizing venulitis: A sequential analysis of the morphological alterations occurring after mast cell degranulation in a patient with a unique syndrome. *Clin Exp Immunol* **32**:46, 1978

109. Wanderer A et al: Urticarial leukocytoclastic vasculitis with cold urticaria. Report of a case and review of the literature. *Arch Dermatol* **119**:145, 1983
110. Kurtz A, Kaplan A: Regional expression of cold urticaria. *J Allergy Clin Immunol* **86**:272, 1990
111. Czarnetzki B, Frosch P, Sprekeler R: Localized cold reflex urticaria. *Br J Dermatol* **104**:83, 1981
112. Ting S, Mansfield L: Localized cold-reflex urticaria. *J Allergy Clin Immunol* **75**:421, 1985
113. Hoffman H, Wanderer A, Broide D: Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. *J Allergy Clin Immunol* **108**:615, 2001
114. Hoffman H et al: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet* **29**:301, 2001
115. Gandhi C et al: Familial atypical cold urticaria: Description of a new hereditary disease. *J Allergy Clin Immunol* **124**:1245, 2009
116. Grant R, Pearson R, Comeau W: Observations on urticaria provoked by emotion, by exercise, and by warming the body. *Clin Sci* **2**:266, 1935
117. Commens C, Greaves M: Tests to establish the diagnosis in cholinergic urticaria. *Br J Dermatol* **98**:47, 1978
118. Herxheimer A: The nervous pathway mediating cholinergic urticaria. *Clin Sci* **15**:195, 1956
119. Soter N et al: Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria. *N Engl J Med* **302**:604, 1980
120. Fukunaga A et al: Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. *J Allergy Clin Immunol* **116**:397, 2005
121. Onn A, Levo Y, Kivity S: Familial cholinergic urticaria. *J Allergy Clin Immunol* **98**:847, 1996
122. Ormerod A et al: Combined cold urticaria and cholinergic urticaria—clinical characterization and laboratory findings. *Br J Dermatol* **118**:621, 1988
123. Sigler R et al: Evaluation of a patient with cold and cholinergic urticaria. *J Allergy Clin Immunol* **63**:35, 1979
124. Kaplan A, Garofalo J: Identification of a new physically induced urticaria: Cold-induced cholinergic urticaria. *J Allergy Clin Immunol* **68**:438, 1981
125. Grant J et al: Local heat urticaria/angioedema: Evidence for histamine release without complement activation. *J Allergy Clin Immunol* **67**:75, 1981
126. Uetsu N et al: The clinical and photobiological characteristics of solar urticaria in 40 patients. *Br J Dermatol* **142**:32, 2000
127. Harber L, Holloway R, Sheatley V: Immunologic and biophysical studies in solar urticaria. *J Invest Dermatol* **41**:439, 1963
128. Sams WJ, Epstein J, Winkelmann R: Solar urticaria. Investigation of pathogenetic mechanisms. *Arch Dermatol* **99**:390, 1969
129. Gigli I et al: Erythropoietic protoporphyria. Photoactivation of the complement system. *J Clin Invest* **66**:517, 1980
130. Lim H et al: Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. *N Engl J Med* **304**:212, 1981
131. Lim H, Poh-Fitzpatrick M, Gigli I: Activation of the complement system in patients with porphyrias after irradiation in vivo. *J Clin Invest* **74**:1961, 1984
132. Hawk J et al: Elevated blood histamine levels and mast cell degranulation in solar urticaria. *Br J Clin Pharmacol* **9**:183, 1980
133. Soter N, Wasserman S, Pathak M: Solar urticaria: Release of mast cell mediators into the circulation after experimental challenge. *J Invest Dermatol* **72**:283, 1979
134. Casale T, Keahey T, Kaliner M: Exercise-induced anaphylactic syndromes. Insights into diagnostic and pathophysiologic features. *JAMA* **255**:2049, 1986
135. Lewis J et al: Exercise-induced urticaria, angioedema, and anaphylactoid episodes. *J Allergy Clin Immunol* **68**:432, 1981
136. Sheffer A, Austen K: Exercise-induced anaphylaxis. *J Allergy Clin Immunol* **66**:106, 1980
137. Sheffer A et al: Exercise-induced anaphylaxis: A distinct form of physical allergy. *J Allergy Clin Immunol* **71**:311, 1983
138. Kidd JM 3rd et al: Food-dependent exercise-induced anaphylaxis. *J Allergy Clin Immunol* **71**:407, 1983
139. Kivity S et al: The effect of food and exercise on the skin response to compound 48/80 in patients with food-associated exercise-induced urticaria-angioedema. *J Allergy Clin Immunol* **81**:1155, 1988
140. Maulitz R, Pratt D, Schocket A: Exercise-induced anaphylactic reaction to shellfish. *J Allergy Clin Immunol* **63**:433, 1979
141. Novey H et al: Postprandial exercise-induced anaphylaxis. *J Allergy Clin Immunol* **71**:498, 1983

142. Shadick N et al: The natural history of exercise-induced anaphylaxis: Survey results from a 10-year follow-up study. *J Allergy Clin Immunol* **104**:123, 1999
143. Luong K, Nguyen L: Aquagenic urticaria: Report of a case and review of the literature. *Ann Allergy Asthma Immunol* **80**:483, 1998
144. Poley GJ, Slater J: Latex allergy. *J Allergy Clin Immunol* **105**:1054, 2000
145. Kurup V, Fink J: The spectrum of immunologic sensitization in latex allergy. *Allergy* **56**:2, 2001
146. Millikan L: Papular urticaria. In: *Urticaria and Angioedema*, edited by M Greaves, A Kaplan. Basel, Marcel Dekker, 2004, p. 251
147. Pixley R, Schapira M, Colman R: The regulation of human factor XIIIa by plasma proteinase inhibitors. *J Biol Chem* **260**:1723, 1985
148. Schreiber A, Kaplan A, Austen K: Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. *J Clin Invest* **52**:1402, 1973
149. Harpel P, Lewin M, Kaplan A: Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. *J Biol Chem* **260**:4257, 1985
150. Wuillemin W et al: Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. *Blood* **85**:1517, 1995
151. Donaldson V, Evans R: A biochemical abnormality in hereditary angioneurotic edema. *Am J Med* **35**:37, 1963
152. Kramer J et al: Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. *J Clin Invest* **87**:1614, 1991
153. Caldwell J et al: Acquired C1 inhibitor deficiency in lymphosarcoma. *Clin Immunol Immunopathol* **1**:39, 1972
154. Hauptmann G et al: Acquired C1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. *Blut* **32**:195, 1976
155. Schreiber A et al: Acquired angioedema with lymphoproliferative disorder: Association of C1 inhibitor deficiency with cellular abnormality. *Blood* **48**:567, 1976
156. Donaldson V, Hess E, McAdams A: Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. *Ann Intern Med* **86**:312, 1977
157. Geha R et al: Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. *N Engl J Med* **312**:534, 1985
158. Alsenz J, Bork K, Loos M: Autoantibody-mediated acquired deficiency of C1 inhibitor. *N Engl J Med* **316**:1360, 1987
159. Malbran A et al: Acquired angioedema: Observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. *J Allergy Clin Immunol* **81**:1199, 1988
160. Zuraw B, Curd J: Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. *J Clin Invest* **78**:567, 1986
161. He S, Sim R, Whaley K: Mechanism of action of anti-C1-inhibitor autoantibodies: Prevention of the formation of stable C1s-C1-inh complexes. *Mol Med* **4**:119, 1998
162. Jackson J et al: Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. *J Clin Invest* **83**:698, 1989
163. Austen KF, Sheffer AL: Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. *N Engl J Med* **272**:649, 1965
164. Zuraw B, Sugimoto S, Curd J: The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. *J Allergy Clin Immunol* **78**:1115, 1986
165. Curd J, Yelvington M, Burrige N: Generation of bradykinin during incubation of hereditary angioedema plasma. *Mol Immunol* **19**:1365, 1983
166. Fields T, Ghebrehiwet B, Kaplan AP: Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. *J Allergy Clin Immunol* **72**:54, 1983
167. Shoemaker L et al: Hereditary angioneurotic oedema: Characterization of plasma kinin and vascular permeability-enhancing activities. *Clin Exp Immunol* **95**:22, 1994
168. Juhlin L, Michaelsson G: Vascular reactions in hereditary angioneurotic edema. *Acta Derm Venereol* **40**:20, 1969
169. Nussberger J et al: Plasma bradykinin in angioedema. *Lancet* **351**:1693, 1998
170. Schapira M et al: Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. *N Engl J Med* **308**:1050, 1983

171. Talamo R, Haber E, Austen K: A radioimmunoassay for bradykinin in plasma and synovial fluid. *J Lab Clin Med* 74:816, 1969
172. Ghebrehiwet B et al: Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. *J Clin Invest* 71:1450, 1983
173. Curd J, Prograis LJ, Cochrane C: Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. *N Engl J Med* 152:742, 1980
174. Cugno M et al: Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. *Immunopharmacology* 33:361, 1996
175. Zahedi R et al: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443→Val substitution and functional analysis of the recombinant mutant protein. *J Clin Invest* 95:1299, 1995
176. Zahedi R, Wisnieski J, Davis AE 3rd: Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: Inhibition of complement and contact system proteases. *J Immunol* 159:983, 1997
177. Nussberger J et al: Local bradykinin generation in hereditary angioedema. *J Allergy Clin Immunol* 104:1321, 1999
178. Han E et al: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. *J Clin Invest* 8:1057, 2002
179. Bork K et al: Hereditary angioedema with normal C1-inhibitor activity in women. *Lancet* 356:213, 2000
180. Dewald G, Bork K: Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. *Biochem Biophys Res Commun* 343:1286, 2006
181. Bork K, Gul D, Dewald G: Hereditary angioedema with normal C1 inhibitor in a family with affected women and men. *Br J Dermatol* 154:542, 2006
182. Sabroe R, Black A: Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. *Br J Dermatol* 136:153, 1997
183. Kaplan A, Greaves M: Angioedema. *J Am Acad Dermatol* 53:373, 2005
184. Alabaster V, Bakhle Y: Converting enzyme and bradykinin use in the lung. *Circ Res* 31:72, 1992
185. Joseph K, Tholanikunnel B, Kaplan A: Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. *Proc Natl Acad Sci U S A* 99:896, 2002
186. Shariat-Madar Z, Mahdi F, Schmaier A: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. *J Biol Chem* 277:17962, 2002
187. Soter N, Austen K, Gigli I: Urticaria and arthralgias as manifestations of necrotizing angiitis (vasculitis). *J Invest Dermatol* 63:485, 1974
188. Soter N et al: Two distinct cellular patterns in cutaneous necrotizing angiitis. *J Invest Dermatol* 66:344, 1976
189. Agnello V et al: C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: Characterization of high and low molecular weight types. *J Exp Med* 134:228s, 1971
190. Feig P et al: Vasculitis with urticaria, hypocomplementemia, and multiple system involvement. *JAMA* 236:2065, 1976
191. Gammon W, Wheeler CJ: Urticarial vasculitis: Report of a case and review of the literature. *Arch Dermatol* 115:76, 1979
192. Ludivico C, Myers A, Maurer K: Hypocomplementemic urticarial vasculitis with glomerulonephritis and pseudotumor cerebri. *Arth Rheum* 22:1024, 1979
193. Marder R et al: C1q deficiency associated with urticarial-like lesions and cutaneous vasculitis. *Am J Med* 61:560, 1976
194. McDuffie F et al: Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome. *Mayo Clin Proc* 48:340, 1973
195. Moorthy A, Pringle D: Urticaria, vasculitis, hypocomplementemia, and immune-complex glomerulonephritis. *Arch Pathol Lab Med* 106:68, 1982
196. Wisnieski J, Naff G: Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. *Arth Rheum* 32:1119, 1989
197. Zeiss C et al: A hypocomplementemic vasculitic urticarial syndrome. Report of four new cases and definition of the disease. *Am J Med* 68:867, 1980
198. Mortureux P et al: Acute urticaria in infancy and early childhood: A prospective study. *Arch Dermatol* 134:319, 1998
199. Szczeklik A, Gryglewski R, Czerniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. *Br Med J* 1:67, 1975

200. Mastalerz L et al: Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma. *J Allergy Clin Immunol* **113**:771, 2004
201. Sanchez Borges M et al: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. *Ann Allergy Asthma Immunol* **87**:201, 2001
202. Israel E et al: The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. *Am Rev Respir Dis* **148**:1447, 1993
203. Di Campi C et al: Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. *Dig Dis Sci* **43**:1226, 1998
204. Liutu M et al: Etiologic aspects of chronic urticaria. *Int J Dermatol* **37**:515, 1998
205. Wedi B et al: Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria. *Int Arch Allergy Immunol* **116**:288, 1998
206. Becker H, Meyer M, Paul E: Remission ratio of chronic urticaria – “spontaneous” healing or result of eradication of Helicobacter pylori? *Hautarzt* **49**:907, 1998
207. Hidvegi B et al: The effect of heat-inactivated Helicobacter pylori on the blastogenic response of peripheral blood mononuclear cells of patients with chronic urticaria. *Int Arch Allergy Immunol* **126**:167, 2001
208. Schnyder B, Helbling A, Pichler W: Chronic idiopathic urticaria: Natural course and association with Helicobacter pylori infection. *Int Arch Allergy Immunol* **119**:60, 1999
209. Valsecchi R, Pigatto P: Chronic urticaria and Helicobacter pylori. *Acta Derm Venereol* **78**:440, 1998
210. Greaves M: Chronic idiopathic urticaria and Helicobacter pylori—Not directly causative but could there be a link. *Allergy Clin Immunol Int* **13**:23, 2001
211. Gleich G et al: Episodic angioedema associated with eosinophilia. *N Engl J Med* **310**:1621, 1984
212. Lipsker D et al: The Schnitzler syndrome. Four new cases and review of the literature. *Medicine* **80**:37, 2001
213. Sabroe R et al: The autologous serum skin test: A screening test for autoantibodies in chronic idiopathic urticaria. *Br J Dermatol* **140**:446, 1999
214. Hoskin S et al: Basophil infiltration of weals in chronic idiopathic urticaria *J Allergy Clin Immunol* **109**:S87, 2002
215. Hermes B et al: Upregulation of TNF- α and IL-3 expression in lesional and uninvolved skin in different types of urticaria. *J Allergy Clin Immunol* **103**:307, 1999
216. Toubi E et al: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. *J Clin Immunol* **20**:371, 2000
217. Kaplan A: What the first 10,000 patients with chronic urticaria have taught me: a personal journey. *J Allergy Clin Immunol* **123**:713, 2009
218. Grob J, Gaudy-Marqueste C: Urticaria and quality of life. *Clin Rev Allergy Immunol* **30**:47, 2006
219. O'Donnell B et al: The impact of chronic urticaria on the quality of life. *Br J Dermatol* **136**:197, 1997
220. Poon E et al: The extent and nature of disability in different urticarial conditions. *Br J Dermatol* **140**:667, 1999
221. Moore-Robinson M, Warin R: Some clinical aspects of cholinergic urticaria. *Br J Dermatol* **80**:794, 1968
222. Zuberbier T et al: Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. *Dermatology* **193**:324, 1996
223. Keahey T, Greaves M: Cold urticaria. Dissociation of cold-evoked histamine release and urticaria following cold challenge. *Arch Dermatol* **116**:174, 1980
224. Sigler R et al: The role of cyproheptadine in the treatment of cold urticaria. *J Allergy Clin Immunol* **65**:309, 1980
225. Wanderer A, Ellis E: Treatment of cold urticaria with cyproheptadine. *J Allergy Clin Immunol* **48**:366, 1971
226. Wanderer A, St Pierre J, Ellis E: Primary acquired cold urticaria. Double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. *Arch Dermatol* **131**:1375, 1977
227. Kaplan A: Clinical practice. Chronic urticaria and angioedema. *N Engl J Med* **346**:175, 2002
228. Grattan C et al: Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. *Br J Dermatol* **143**:365, 2000
229. Toubi E et al: Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. *Allergy* **52**:312, 1997
230. Grattan C et al: Plasmapheresis for severe, unremitting, chronic urticaria. *Lancet* **339**:1078, 1992
231. O'Donnell B et al: Intravenous immunoglobulin in autoimmune chronic urticaria. *Br J Dermatol* **138**:101, 1998

232. Kaplan A et al: Treatment of chronic autoimmune urticaria with omalizumab. *J Allergy Clin Immunol* 122:569, 2008
233. Dreyfus D: Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema. *Ann Allergy Asthma Immunol* 100:624, 2008
234. Spector S, Tan R: Effect of omalizumab on patients with chronic urticaria. *Ann Allergy Asthma Immunol* 99:190, 2007
235. Lopez L et al: The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to hydroxychloroquine. *J Allergy Clin Immunol* 73:600, 1984
236. Bork K et al: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). *J Allergy Clin Immunol* 119:1497, 2007
237. Schneider L et al: Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. *J Allergy Clin Immunol* 120:416, 2007
238. Sheffer A, Fearon D, Austen K: Hereditary angioedema: A decade of management with stanazolol. *J Allergy Clin Immunol* 80:855, 1987
239. Sheffer AL, Fearon DT, Austen KF: Clinical and biochemical effects of stanazolol therapy for hereditary angioedema. *J Allergy Clin Immunol* 68:181, 1981
240. Sheffer A, Austen K, Rosen F: Tranexamic acid therapy in hereditary angioneurotic edema. *N Engl J Med* 287:452, 1972
241. Frank M et al: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. *N Engl J Med* 286:808, 1972
242. Gelfand JA et al: Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. *N Engl J Med* 295:1444, 1976